Pyxis Oncology Files 8-K

Ticker: PYXS · Form: 8-K · Filed: 2024-11-20T00:00:00.000Z

Sentiment: neutral

Topics: sec-filing, 8-k, disclosure

TL;DR

Pyxis Oncology filed a routine 8-K, no major news.

AI Summary

Pyxis Oncology, Inc. filed an 8-K on November 20, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements for this form.

Why It Matters

This filing indicates Pyxis Oncology is making standard disclosures to the SEC, which is a routine part of maintaining public company status.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report with no indication of significant new risks or material adverse events.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing by Pyxis Oncology, Inc.?

The primary purpose of this 8-K filing is to report on Regulation FD Disclosure and Financial Statements and Exhibits, as indicated in the filing.

On what date was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on November 20, 2024.

In which state was Pyxis Oncology, Inc. incorporated?

Pyxis Oncology, Inc. was incorporated in Delaware.

What is the principal executive office address for Pyxis Oncology, Inc.?

The principal executive office address for Pyxis Oncology, Inc. is 321 Harrison Avenue, Boston, Massachusetts 02118.

Does this 8-K filing disclose any specific new financial results or material events?

Based on the provided text, this 8-K filing is primarily for standard reporting categories (Regulation FD Disclosure, Financial Statements and Exhibits) and does not detail specific new financial results or material events.

Filing Stats: 530 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2024-11-20 16:06:44

Key Financial Figures

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure On November 20, 2024, Pyxis Oncology, Inc. (the "Company") provided a corporate update and issued a press release announcing positive initial dose escalation data from the ongoing Phase 1 clinical study evaluating PYX-201 in multiple types of solid tumors. A copy of the corporate presentation is attached as Exhibit 99.1. and the press release is attached as Exhibit 99.2 to this Current Report on Form 8-K. The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Presentation dated November 20, 2024 99.2 Press Release dated November 20, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Pyxis Oncology, Inc. Date: November 20, 2024 By: /s/ Pamela Connealy Pamela Connealy Chief Financial Officer and Chief Operating Officer

View on Read The Filing